News Story: Full Text
Sponsored By
Orbus Therapeutics Inc Clinical Trial for Recurrent Anaplastic Astrocytomas
Please Click On The Above Banner For More Details
Braintumor Website


Phase II trial of motexafin gadolinium (MGd, Xcytrin®) and cranial radiation in newly diagnosed glioblastoma multiforme (GBM) Motexafin gadolinium in combination with cranial radiation is tolerable for GBM patients early follow-up shows a 6 month survival of 84%

Posted on: 05/26/2002

Phase II trial of motexafin gadolinium (MGd, Xcytrin®) and cranial radiation in newly diagnosed glioblastoma multiforme (GBM)

John Suh, Eric Chang, Robert Timmerman, Mark Leibenhaut, Yoshiya Yamada, Laurie E Gaspar, Aroor Rao, Jennifer Smith, See Phan, W K Alfred Yung, Minesh P Mehta, Cleveland Clinic, Cleveland, OH; M.D. Anderson Cancer Center, Houston, TX; Indiana University, Indianapolis, IN; Radiological Associates of Sacramento, Sacramento, CA; Memorial Sloan-Kettering, New York, NY; University of Colorado Health Sciences Center, Denver, CO; Kaiser Permanente, Los Angeles, CA; Pharmacyclics Inc, Sunnyvale, CA; University of Wisconsin, Madison, WI.

Pre-clinical experiments have demonstrated increased cell death in glioma cells treated with MGd and radiation compared to those treated with radiation alone. Following early promising results from a phase I trial, we recently completed a Phase II trial of MGd with radiation therapy (RT) for GBM and report preliminary results herein. Twenty five GBM patients (17 male, 8 female, age range 33-80, median age 59 years) underwent total (4) or partial (14) resection, or biopsy only (7), and subsequently received 46 Gy ( 2 Gy x 23) to the MRI T2 abnormality (with a 2 cm margin) and an additional boost dose of 14 Gy (2 Gy x 7; total dose 60 Gy) to the MR enhancing abnormality with a 2 cm margin. MGd was administered at 5 mg/kg, 2-5 hours prior to RT, daily for the first 10 fractions, and 3 x per week thereafter for a total of 22 doses. By the RTOG RPA prognostic classification system, there were 4 class III patients, 10 IV’s, 10 V’s and 1 VI. Eighteen patients completed all 22 doses of MGd and 22 patients completed >80%. Twenty-four patients completed the planned radiation therapy. Grade 3 or worse toxicities during the treatment period included DVT (16%), seizures (12%), pneumonia (12%), and increased GGTP (12%). Common drug related grade 1 or 2 toxicities included reversible skin (88%) and urine (72%) discoloration, vesiculobullous rash (60%), transient paresthesias (56%), and asthenia (40%). Two patients had protocol specified interruptions in treatment for transient grade 3 liver function abnormalities, the defined dose-limiting toxicity for MGd. With a median follow-up of 5.5 months, median survival has not been reached., 6 month survival is 84%.

Conclusion: Motexafin gadolinium (22 doses, 5mg/kg/d) in combination with cranial radiation (60 Gy in 30 fractions) is tolerable for GBM patients. Early follow-up shows a 6 month survival of 84%. One-year survival data will be available for presentation.

Source: ASCO 2002 Annual Conference
Click HERE to return to brain tumor news headlines

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557